BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Safety Notice for the contrast media injector system OptiVantage™ DH, Mallinckrodt Pharmaceuticals

Product group Injections / Infusions / Transfusions / Dialysis - infusion technology
Reference 03764/09

The company Mallinckrodt Pharmaceuticals notified of a safe fill technique when filling syringes with the contrast media injector system Optivantage DH. The manufacturer intents to clarify additional closed system fill techniques. Instructions and methods for an appropriate risk minimization regarding aseptic fill technique are available in the updated Operators Manual.

Safety Notice for the contrast media injector system OptiVantage™ DH, Mallinckrodt Pharmaceuticals , Download_VeroeffentlichtAm_EN PDF, 73KB, File does not meet accessibility standards